@article{c5351f941ddc4b088f917e1c9e8d1e7d,
title = "Experiencing bullying's impact on adolescent depression and anxiety: Mediating role of adolescent resilience",
abstract = "Youth who experience bullying are at risk for psychopathology, indicating the necessity of identifying factors that may protect against the deleterious effects of being bullied. The present study expands upon prior research by examining resilience as a mediator of the effects of experiencing bullying on depression and anxiety within a sample of 2155 adolescents. Results indicated that youth who experienced bullying were more likely to have higher symptoms of depression and anxiety and lower resilience, while higher levels of resilience were associated with fewer symptoms of depression and anxiety. Resilience partially mediated the associations of experiencing bullying with depression and anxiety symptoms, suggesting that resilience may serve as a protective factor for adolescents who experience bullying. These findings have implications for programming that seeks to address bullying, peer victimization, and promotion of adolescent mental health.",
keywords = "Bullying, Mental health, Peer victimization, Resilience, Youth",
author = "Anderson, {Jacqueline R.} and Taryn Mayes and Anne Fuller and Jennifer Hughes and Abu Minhajuddin and Trivedi, {Madhukar H}",
note = "Funding Information: Dr. Hughes has served as Youth Aware of Mental Health (YAM) trainer, consulting for Mental Health in Mind International. Dr. Hughes also receives royalties from Guilford Press. Dr. Trivedi has served as an adviser or consultant for Abbott Laboratories, Abdi Ibrahim, Akzo (Organon Pharmaceuticals), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb, Cephalon, Cerecor, CME Institute of Physicians, Concert Pharmaceuticals, Eli Lilly, Evotec, Fabre Kramer Pharmaceuticals, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, Janssen Pharmaceutica Products, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Pfizer, PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products, Sepracor, Shire Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories; he has received grants or research support from the Agency for Healthcare Research and Quality, Cyberonics, NARSAD, NIDA, and NIMH. Drs. Anderson , Mayes , Fuller , and Minhajuddin have no disclosures to report. Funding Information: The YAM program was funded in part by the Rees-Jones Foundation, National Institute of Health (UL1 TR001105), W.W. Caruth Jr. Foundation, and the Hersh Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the various funding organizations. In addition, this work was funded in part by the Center for Depression Research and Clinical Care (PI: Madhukar Trivedi). Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",
year = "2022",
month = aug,
day = "1",
doi = "10.1016/j.jad.2022.04.003",
language = "English (US)",
volume = "310",
pages = "477--483",
journal = "Journal of affective disorders",
issn = "0165-0327",
publisher = "Elsevier",
}